Sean McCutcheon
Stock Analyst at Raymond James
(4.51)
# 1,116
Out of 4,662 analysts
41
Total ratings
46.7%
Success rate
42.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Maintained: Buy | $11 | $2.19 | +402.28% | 3 | Aug 6, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $56 | $33.11 | +69.13% | 1 | Jul 31, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $19 → $26 | $20.74 | +25.36% | 2 | May 19, 2026 | |
| ENGN enGene Therapeutics | Maintained: Buy | $27 → $4 | $1.85 | +116.22% | 5 | May 8, 2026 | |
| CMPX Compass Therapeutics | Downgraded: Hold | n/a | $2.48 | - | 3 | Apr 28, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | $12 → $19 | $9.77 | +94.47% | 4 | Feb 24, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Initiated Coverage: Buy | $24 | $9.60 | +150.00% | 1 | Jan 9, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $72 → $76 | $214.66 | -64.60% | 2 | Oct 17, 2025 | |
| RGNX REGENXBIO | Reiterated: Buy | $29 | $12.02 | +141.26% | 5 | Sep 5, 2025 | |
| XNCR Xencor | Maintained: Buy | $40 | $27.52 | n/a | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $29.36 | n/a | 4 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $67.61 | n/a | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $840.84 | n/a | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $17.52 | n/a | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $22.60 | n/a | 3 | Jun 13, 2025 |
Black Diamond Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $11
Current: $2.19
Upside: +402.28%
Faeth Therapeutics
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $56
Current: $33.11
Upside: +69.13%
Relay Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $19 → $26
Current: $20.74
Upside: +25.36%
enGene Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $27 → $4
Current: $1.85
Upside: +116.22%
Compass Therapeutics
Apr 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $2.48
Upside: -
Vir Biotechnology
Feb 24, 2026
Maintained: Buy
Price Target: $12 → $19
Current: $9.77
Upside: +94.47%
BridgeBio Oncology Therapeutics
Jan 9, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $9.60
Upside: +150.00%
Revolution Medicines
Oct 17, 2025
Maintained: Buy
Price Target: $72 → $76
Current: $214.66
Upside: -64.60%
REGENXBIO
Sep 5, 2025
Reiterated: Buy
Price Target: $29
Current: $12.02
Upside: +141.26%
Xencor
Aug 7, 2025
Maintained: Buy
Price Target: $40
Current: $27.52
Upside: n/a
Jul 24, 2025
Reiterated: Hold
Price Target: n/a
Current: $29.36
Upside: n/a
Jul 17, 2025
Maintained: Hold
Price Target: n/a
Current: $67.61
Upside: n/a
Jul 17, 2025
Maintained: Hold
Price Target: n/a
Current: $840.84
Upside: n/a
Jul 11, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $17.52
Upside: n/a
Jun 13, 2025
Maintained: Buy
Price Target: $86
Current: $22.60
Upside: n/a